Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39934 | 0.84 | CD274 (0.60) | CD274TDP1SMN1; SMN2DRD2POLB | |
| SCHEMBL4753694 | 0.82 | CD274 (0.54) | ALDH1A1CD274TDP1SMN1; SMN2SIGMAR1 | |
| SCHEMBL39968 | 0.81 | LMNA (0.58) | ALDH1A1CD274DRD2 | |
| SCHEMBL9093109 | 0.79 | CD274 (0.53) | CD274TDP1SMN1; SMN2DRD2POLB | |
| SCHEMBL97212 | 0.78 | LMNA (0.51) | ALDH1A1TDP1BRD4SMN1; SMN2DRD2 | |
| SCHEMBL2850188 | 0.77 | CD274 (0.51) | ALDH1A1CD274TDP1DRD2 | |
| SCHEMBL12014420 | 0.77 | ATM (0.48) | ALDH1A1TDP1SMN1; SMN2ATM | |
| SCHEMBL23291143 | 0.76 | BRD4 (0.53) | ALDH1A1CD274BRD4SMN1; SMN2POLB | |
| SCHEMBL12986900 | 0.76 | CTSK (0.45) | ALDH1A1CD274TDP1SMN1; SMN2ATM | |
| SCHEMBL21230528 | 0.76 | CTSK (0.45) | ALDH1A1CD274TDP1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | ALDH1A1 852/4885CD274 4112/4885TDP1 1226/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | ALDH1A1 2474/4885CD274 4677/4885TDP1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.